API production starts at Evonik's new plant

Related tags Pharmaceutical drug Pharmacology

Production has begun at the US API plant German chemicals firm Evonik Industries recently bought from drugmaker Eli Lilly.

The Tippercanoe Laboratories unit in Lafayette, Indiana will manufacture a range of active pharmaceutical ingredients (API) for pharma firms, beginning with Lilly, on a contractual basis as part of an expansion of Evonik’s healthcare arm.

Evonik said that the facility, which employs a workforce of 650 people, significantly strengthens its “exclusive synthesis business in the US and offers scope for further long-term growth​.”

The 2,400 acre site was sold by which was sold by Lilly late last year​ as part of the drug major’s strategy to reduce internal manufacturing capacity and buy in more APIs and drug intermediates.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...